Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 719-725

  Schroeder, Patricia E ^a   Wang, Gu Qi ^a   Burczynski, Frank J ^a   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; CALCIUM ION; DIHYDROOROTASE; DIHYDROPYRIMIDINASE; DRUG METABOLITE; IRON COMPLEX; MAGNESIUM ION; N,N' (1 METHYL 1 ETHANEDIYL)BIS[[N (2 AMINO 2 OXOEHTYL)]]GLYCINE; OXYGEN RADICAL; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYDROLYSIS; LIVER CELL; MUSCLE CELL; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; RING OPENING;

ADULT; ANIMALS; CARDIOTONIC AGENTS; FEMALE; HEPATOCYTES; HUMANS; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE;

STAPHYLOCOCCUS PHAGE 187;

EID: 18844435708     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.003186     Document Type: Article

References (34)

1. Burczynski FJ and Cai ZS (1994) Palmitate uptake by hepatocyte suspensions: effect of albumin. Am J Physiol 267:G371-G379.
2. Buss JL and Hasinoff BB (1993) The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95.
3. Buss JL and Hasinoff BB (1997) Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J Inorg Biochem 68:101-108.
4. Cheng KL, Ueno K, and Imamura T (1982) CAC Handbook of Organic Analytical Reagents. CRC Press, Boca Raton, FL.
5. Christopherson RI and Jones ME (1980) The effects of pH and inhibitors upon the catalytic activity of the dihydroorotase of multienzymatic protein pyrl-3 from mouse Ehrlich ascites carcinoma. J Biol Chem 254:12506-12512.
6. Dawson KM (1975) Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol 24:2249-2253.
7. Diop NK, Vitellaro LK, Arnold P, Shang M, and Marusak RA (2000) Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics and DNA cleavage activity. J Inorg Biochem 78:209-216.
8. Doroshow JH (1995) Role of reactive oxygen metabolism in cardiac toxicity of anthracycline antibiotics, in Anthracycline Antibiotics: New Analogues, Methods of Delivery and Mechanisms of Action (Priebe W ed), pp 259-267, American Chemical Society, Washington, DC.
9. Doroshow JH, Burke TG, van-Balgooy J, Alqnan S, and Verhoef V (1991) Cellular pharmacology of ICRF-187 (187, ADR-529) in adult rat heart myocytes. Proc Am Assoc Cancer Res 32:332.
10. Dudley KH, Butler TC, and Bius DL (1974) The role of dihydropyrimidinase in the metabolism of some hydantoin and succinimide drugs. Drug Metab Dispos 2:103-112.
11. i. J Biol Chem 267:7545-7552.
12. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, and Nonaka M (1996) A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 180:157-163.
13. Hasinoff BB (1990) The hydrolysis-activation of the doxorubicin cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Metab Dispos 18:344-349.
14. Hasinoff BB (1993) Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos 21:883-888.
15. Hasinoff BB (1994a) An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane) and its one-ring opened intermediates. Int J Pharm 107:67-76.
16. Hasinoff BB (1994b) Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 83:64-67.
17. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25 (Suppl 10):3-9.
18. Hasinoff BB and Aoyama RG (1999a) Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat. Drug Metab Dispos 27:265-268.
19. Hasinoff BB and Aoyama RG (1999b) Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). Chirality 11:286-290.
20. Hasinoff BB, Hellmann K, Herman EH, and Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28.
21. Hasinoff BB, Reinders FX, and Clark V (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Dispos 19:74-80.
22. Hasinoff BB, Schroeder PE, and Patel D (2003) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64:670-678.
23. Hasinoff BB, Venkataram S, Singh M, and Kuschak TI (1994) Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 24:977-987.
24. Höchster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, and Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730.
25. Jones D (2002) Pharmaceutical Statistics. Pharmaceutical Press, London.
26. Kennedy J (1974) Dihydroorotase from rat liver: purification, properties and regulatory role in pyrimidine biosynthesis. Arch Biochem Biophys 160:358-365.
27. Luquita A, Gennaro AM, and Rasia M (2001) Influence of adsorbed plasma proteins on erythrocyte rheological properties: in vitro and ex vivo studies. Pflugers Arch 443:78-83.
28. Malisza KL and Hasinoff BB (1995) Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/ hypoxanthine system. Arch Biochem Biophys 321:51-60.
29. Meyers CE (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25 (Suppl 10):10-14.
30. Pradhan TK and Sander EG (1973) Noncompetitive inhibition by unsubstituted sulfonamides of dihydroorotase from Zymobacterium oroticum. Life Sci 13:1747-1752.
31. Schroeder PE, Davidson JN, and Hasinoff BB (2002) Dihydroorotase catalyzes the ring-opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 30:1431-1435.
32. Schroeder PE and Hasinoff BB (2002) The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol 50:509-513.
33. Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, and Hasinoff BB (2003) Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 52:167-174.
34. Smith LH and Baker FA (1959) Pyrimidine metabolism in man. I. The biosynthesis of orotic acid. J Clin Investig 38:798-809.